This fund endeavors to meet its investment goals by typically committing a minimum of 80% of its net assets (including any borrowed capital used for investment) to companies its portfolio managers determine have a primary focus on life sciences. Moreover, a core tenet of the fund's approach to life science enterprises is a fundamental policy to ordinarily allocate at least 25% of its total assets to businesses formally classified within the "life sciences" sector.